SynCores

SynCores is a clinical-stage biotechnology company based in Taiwan that specializes in the development of innovative radiopharmaceuticals for cancer diagnosis and therapy. The company leverages its proprietary "Core-Shell" technology platform to design targeted molecular imaging agents and therapeutic radionuclides, facilitating a theranostic approach to oncology. Its lead program, SC-101, is a PSMA-targeted radiopharmaceutical currently in Phase 2 clinical trials for the management of prostate cancer. Additionally, SynCores is advancing a pipeline of tracers targeting the fibroblast activation protein (FAP) to address a broad range of solid tumors. As a subsidiary of the Sinphar Group, the company benefits from established pharmaceutical manufacturing and distribution networks in the Asia-Pacific region.